Matarin Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Matarin Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-27,570	Closed	-$102K	–	316
2018 Q2	$102K	Sell	27,570 -5,272	-16%	-$24.4K	0.01%	294
2018 Q1	$126K	Sell	32,842 -3,385	-9%	-$14.2K	0.01%	290
2017 Q4	$130K	Hold	36,227	–	–	0.01%	287
2017 Q3	$143K	Buy	+36,227	New	+$166K	0.01%	284

Other funds holding AGTC

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

Matarin Capital Management's AGTC Position: Q3 2018 in Review

Matarin Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q3 2018, closing a stake of 27,570 shares — an estimated $102K sold.

Matarin Capital Management first reported a position in AGTC in Q3 2017 and held it in 4 quarters. The position peaked at $143K in Q3 2017. 61 funds tracked by Wall St. Rank hold AGTC as of Q3 2018.

Matarin Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q3 2018 after selling out during the quarter.
Matarin Capital Management sold 27,570 Applied Genetic Technologies Corporation shares in Q3 2018, an estimated $102K.
Matarin Capital Management first reported a position in Applied Genetic Technologies Corporation in Q3 2017 and held it in 4 quarters.
Matarin Capital Management's Applied Genetic Technologies Corporation position peaked at $143K in Q3 2017.
61 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q3 2018.

Based on Matarin Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.